# Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.7555/JBR.30.20150114</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662084">http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662084</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer

Nisha Gupta, Dan G. Duda

Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA.

Abstract

Metastatic prostate cancer is one of the leading causes of cancer-related death in men. The primary site of metastasis from prostate cancers is the bone. During the last decade, multiple studies have pointed to the role of the stromal cell-derived factor 1 alpha (SDF1α)/CXCR4 axis in the metastatic spread of the disease, but the mechanisms that underlie this effect are still incompletely understood. In this review, we summarize the current understanding of the role of the SDF1α/CXCR4 pathway in bone metastatic prostate cancer. We also discuss the therapeutic potential of disrupting the interaction between prostate tumor cells and bone environment with focus on the SDF1α pathway.

Keywords: SDF1α, CXCR4, bone metastasis, prostate cancer

Introduction

Prostate cancer is the second most common cancer among men and the second leading cause of cancer-related death in men in the United States. Most prostate cancers (93%) are found when the disease is confined to the prostate and nearby organs, is indolent, and has a good prognosis. However, the 5-year survival rate sharply declines from 90% for localized prostate cancer to 28% for metastatic prostate cancer[1]. The skeletal bones are the preferential sites of metastasis from prostate cancer[2]. In fact, homing of metastatic prostate cancer cells to bone tissue is associated with the presence and activity of osteoblast lineage cells[3-6]. However, the precise mechanism leading to prostate cancer bone metastasis remains poorly understood. The process of metastasis is known to be the result of several necessary sequential steps - including the survival of tumor cells at distant locations and adaption to the foreign microenvironment, thereby facilitating cell proliferation and the formation of a metastatic lesion. The aggressive and highly metastatic capacity makes the treatment of advanced prostate cancer a major challenge[7]. The therapeutic options currently available (local radiation, cytotoxics, vaccine therapy, and hormonal therapies) are palliative and cannot control disease progression. Despite the clinical significance of bone metastatic prostate cancer, we only know little about the molecular mechanisms underlying the progression of this disease.

Role of chemokines in metastatic prostate cancer: the SDF1α pathway

Chemokines are a family of small (8 to 12 kDa) peptides that function as chemo-attractant cytokines that mediate and regulate cell activation, differentiation and trafficking. Chemokines are known to interact with a superfamily of 20 C-C or C-X-C trans-membrane domain
heterotrimeric G protein-coupled receptors (GPCR)\textsuperscript{[31]}. The stromal-derived factor 1 alpha (SDF1\textalpha{}), also referred to as CXCL12, binds and initiates signaling through its receptors C-X-C chemokine receptor type 4 (CXCR4) and C-X-C chemokine receptor type 7 (CXCR7)\textsuperscript{[8,10]}. The SDF1\textalpha{}/CXCR4 signaling has been recognized as a critical pathway for the homing and tissue retention of hematopoietic progenitor/stem cells in the bone marrow microenvironment\textsuperscript{[11,12]}. Several studies have shown that CXCR4 plays a crucial and pleiotropic role in malignant tumor progression, including prostate cancer, particularly in the metastatic spread of the disease. High levels of the chemokine receptor CXCR4 induce a more aggressive phenotype in prostate cancer cells\textsuperscript{[12,13]}. Interestingly, the bone environment - in which SDF1\textalpha{} is particularly highly expressed - is also the most common metastatic site of prostate cancer. Moreover, metastatic prostate cancer cells localized in the bone metastatic lesions express higher SDF1\textalpha{}/CXCR4 levels relative to the cells present in primary tumors and lymph node metastatic lesions\textsuperscript{[6,14]}. These findings suggest that the activation of the SDF1\textalpha{}/ CXCR4 pathway may play a pivotal role in prostate cancer bone metastases. This review focuses primarily on the SDF1\textalpha{}/CXCR4 axis regulation, on the pre-clinical observations made in bone metastatic prostate cancer metastases, and their implication for development of more effective treatment strategies in the future.

The SDF1\textalpha{}/CXCR4 axis: Role in bone metastatic prostate cancer

SDF1\textalpha{} signaling can be activated via CXCR4 in prostate cancer cells driven by the loss of phosphatase and tensin homolog (PTEN) and subsequent activation of PI3K/Akt pathway. Akt1-associated SDF1\textalpha{}/CXCR4 signaling can promote prostate tumor growth\textsuperscript{[15]}. Moreover, silencing of CXCR4 can lead to a significant down-regulation in the secretion of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9), to a delay in primary tumor growth and to inhibition of the incidence of prostate cancer bone metastases\textsuperscript{[16]}. SDF1\textalpha{} is also produced by the bone marrow stromal cells of mesenchymal origin, including osteoblasts, and by vascular endothelial cells\textsuperscript{[5,17,18]}. SDF1 transiently regulates the number and affinity of \(\alpha_\beta_3\) receptors by prostate cancer cells, and increases the expression of the \(\beta_3\) subunit to enhance their metastatic behavior by increasing adhesiveness and invasiveness in bone marrow\textsuperscript{[19]}. Additionally, SDF1\textalpha{} induces the expression of CD164 and blockade of CD164 in prostate cancer cell lines decreases the ability of these cells to adhere to human bone marrow endothelial cells\textsuperscript{[20]}. This suggests that activation and increased expression of CD164 and \(\alpha_\beta_3\) may be important in the metastatic spread of prostate cancer cells to the skeleton. In addition, inhibition of CXCR4 activity alters the homing of quiescent prostate cancer cells to bone. These cells have more potential to form bone metastases than rapidly proliferating prostate cancer cells. Higher levels of CXCR4 are associated with mitotic dormancy that facilitates tumor cell colonization of the bone marrow in prostate cancer\textsuperscript{[21-23]}. These dormant or slow-cycling disseminated prostate cancer cells in bone marrow are more resistant to conventional therapies. It was shown that these cells predominantly express transforming growth factor-beta 2 (TGF-\(\beta_2\)) to maintain SDF1\textalpha{}/CXCR4 overexpression\textsuperscript{[24]}. Several studies showed that metastatic prostate cancers recruit mesenchymal stem cells, which are converted into cancer-associated fibroblasts and facilitate metastasis. In prostate tumors, CXCL16, a ligand for CXCR6, stimulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts, which secrete higher levels of SDF1\textalpha{}. SDF1\textalpha{} binds to CXCR4 on prostate cancer cells and induces an epithelial-to-mesenchymal transition (EMT)\textsuperscript{[25]}. Inhibition of the SDF1\textalpha{}/CXCR4 axis leads to suppression of the bone marrow mesenchymal stem cell-induced prostate cancer stem cell population increase, and to downregulation of the expression of MMP-9, ZEB-1, CD133 and CXCR4\textsuperscript{[26]}. Accumulating evidence suggests that activated hypoxia-inducible factors, HIF-1\textalpha{} and HIF-2\textalpha{}, may induce the expression of EMT program-associated molecules, including Snail, Twist, CXCR4 and angiogenic factors such as VEGF\textsuperscript{[27]}. Interestingly, in an osteosarcoma study, hypoxia-induced CXCR4 expression persisted even after cultured cells were returned to normoxic conditions, suggesting more persistent phenotypic changes\textsuperscript{[28]}. In summary, activation of the SDF1\textalpha{}/CXCR4 pathway may play a critical role via multiple mechanisms: by promoting prostate tumor growth, homing of prostate cancer cells to bone, and facilitating interactions among cancer cells and bone environment (Fig. 1).

The SDF1\textalpha{}/CXCR4 axis in bone metastasis: Beyond prostate cancer

As summarized above, a large amount of data strongly suggest a key role of the SDF1\textalpha{}/CXCR4 pathway in bone metastases from prostate cancer patients. However, the evidence for the involvement of this pathway in other frequent bone metastatic cancers, such as breast cancer, is very limited. Same as in prostate cancer, high levels of CXCR4 expression in breast cancer are associated with early distant and bone metastases. In various bone metastatic breast models, SDF1\textalpha{} expression was regulated by cytokines such as interleukin (IL)-17A, IL-6, macrophage colony-stimulating factor (M-CSF), liver-enriched inhibitory protein (LIP), neuregulin 1 (NRG1), SMAD4, HIF-1, BACH1 and MMP-1\textsuperscript{[29-32]}. Since tumor-stroma interactions
involving the SDF1α/CXCR4 are likely to be equally important in these settings, further understanding in this area may have important implications for understanding bone metastasis in general. Moreover, this improved understanding could potentially allow the development of novel strategies to reduce morbidity and mortality in bone metastatic cancer patients.

**SDF1α and bone metastatic prostate cancer therapy: Future perspective**

The increasing evidence that SDF1α/CXCR4 signaling may contribute to prostate cancer progression and relapse warrants studies of SDF1α/CXCR4 inhibition to target both primary or metastatic lesions. The most studied SDF1α/CXCR4 inhibitor is the CXCR4 antagonist AMD3100, an FDA-approved drug known as plerixafor or Mozobil® and used for hematopoietic stem cell mobilization by bolus injection. AMD3100 has been shown to inhibit primary tumor growth and decrease the incidence of metastases in multiple animal models[33-37]. However, the safety of chronic treatment with a chemokine receptor antagonist remains to be confirmed in patients, given the obvious concerns related to hematologic toxicities.

An alternative approach would be to inhibit the expression of SDF1α/CXCR4 in primary and metastatic prostate cancers, without directly inhibiting CXCR4 signaling. In this respect, it is critical to identify the mechanism by which CXCR4 expression is activated in prostate cancer bone metastases, in particular by hypoxia induced factor (HIF)-1α and HIF-2α may induce the expression of epithelial-to mesenchymal-transition (EMT)-associated molecules snail and twist. In turn, inhibition of SDF-1α could lead to downregulation of the expression of MMP-9, ZEB-1, CD133 and CXCR4 in bone metastatic prostate tumors.

*Figure courtesy of Rekha Gupta and Priscilla R.C. Jain and unsing.*
efficacious immunotherapies. The currently available vaccine has only limited efficacy, and checkpoint inhibitors have failed so far to show promising efficacy in advanced prostate cancer patients. Combining CXCR4 inhibition with checkpoint blockade, with or without radiation therapy, may be a potential strategy to achieve synergy[33]. Once this improved understanding is achieved, preclinical and clinical studies should translate this knowledge into real benefits for bone metastatic prostate cancer patients.

Acknowledgments

DGD’s research is supported by NIH grants R01-CA159258 and P01-CA080124 and by American Cancer Society Grant 120733-RSG-11-073-01-TBG.

References


